Compare Citius Pharmaceuticals Inc (CTXR) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Deutsche Bank AG — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Deutsche Bank AG trades at $33.61 (market cap $63.13B). The key difference: Deutsche Bank AG is far larger — about 4578× Citius Pharmaceuticals Inc's market cap, and Deutsche Bank AG pays a 3.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Deutsche Bank AG for 80 Days on average.
| CTXR | DB | |
|---|---|---|
Market Cap | $13.79M | $63.13B |
Volume | 156,684 | 3,260,488 |
Sector | Health | Financials |
52-Week High | $1.82 | $41.56 |
52-Week Low | $0.48 | $28.37 |
Typical Hold Time | 16 Days | 80 Days |
Enterprise Value | $3.96M | $75.71B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Deutsche Bank (DB) trades at $33.55, down 4.5% amid concerns over Q3 investment banking revenue. The stock shows attractive valuation with P/E of 9.1 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B. Technical indicators signal bearish momentum with price near support at $33. Recent news highlights management's focus on 2028 targets and wealth management growth.
The outlook remains mixed - strong fundamentals and undervaluation present opportunity, but near-term headwinds in investment banking and bearish technicals suggest caution. Key risks include revenue volatility and European economic pressures, while analyst consensus leans neutral with 57.6% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
